AG真人官方

United Therapeutics (UTHR) Q2-25 10-Q highlights

• Sales up 12%: Q2 revenue rose to $798.6 m (vs. $714.9 m), driven by Tyvaso DPI (+22%) and Orenitram (+16%). Six-month revenue reached $1.59 bn (+14%).
• Margin expansion: Gross margin held at 89%; operating income increased 14% to $364.5 m. Diluted EPS climbed 10% to $6.41; YTD EPS $13.02 (+8%).
• Strong cash generation & deleveraging: Operating cash flow $652.9 m (+7%). Paid off $500 m of credit lines; total liabilities down to $734 m (-20% YTD). Cash & equivalents $1.59 bn after $104 m outflow.
• Liquidity: New unsecured revolving credit facility of up to $2.5 bn (undrawn) replaces 2022 agreement.
• Capital allocation: No 2025 buybacks; treasury stock remains 30.2 m shares from 2024 ASR. Share-based comp $69.6 m YTD.
• Litigation update: $72.6 m accrued for Sandoz contract damages; multiple proceedings with Liquidia continue despite Yutrepia launch.
• Product mix: Tyvaso franchise contributes 59% of Q2 sales; Remodulin down 9% YoY.

Balance sheet: Equity $7.17 bn (+11%), assets $7.91 bn. Marketable investments total $3.38 bn; property, plant & equipment up 11% after $107 m RTP real-estate purchase.

United Therapeutics (UTHR) Form 4: EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at an exercise price of $135.42 on 07/24/2025, converting them into common shares. The same day, he disposed of the entire 11,000-share lot through three open-market sales executed under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $303.31, $304.25 and $305.14, generating gross proceeds of roughly $3.3 million and a spread of about $168 per share over the strike price.

Following the transactions Mahon retains 36,781 shares of common stock held directly and continues to hold 99,000 unexercised options (same grant, expiring 03/15/2027). No other classes of securities were affected.

The filing represents routine insider activity disclosed within two business days and does not alter company guidance or fundamentals. Investors often monitor insider sales for sentiment signals; however, the use of a 10b5-1 plan and the retention of a sizable equity stake temper any negative inference.

United Therapeutics Corp. (UTHR) 鈥� Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.

The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon鈥檚 cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.

No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.

On 14 July 2025, Range Resources Corporation (NYSE: RRC) filed a Form 8-K (Item 2.02) disclosing preliminary second-quarter 2025 hedging results.

• Total gain on derivatives: approximately $154.7 million for the three months ended 30 June 2025.
• Net cash receipts from derivative settlements: $31.5 million, broken down as $26.3 million from natural gas, $2.8 million from natural-gas-basis, $1.5 million from NGLs and $0.8 million from oil contracts.

The company emphasized that these figures are preliminary and will be finalized in the forthcoming Form 10-Q and related earnings release. No additional operating metrics were provided.

The sizeable mark-to-market gain and positive cash settlements are expected to enhance reported earnings and liquidity for Q2 2025, although such benefits are inherently volatile and tied to future commodity-price movements.

United Therapeutics Corp. (UTHR) has received a Form 144 filing indicating a planned sale of 11,000 common shares through Morgan Stanley Smith Barney on or after 07/10/2025. The proposed transaction is valued at $3.30 million, based on the filing鈥檚 quoted market value. The company has 45.11 million shares outstanding, so the contemplated sale represents roughly 0.024 % of total shares.

The filer, identified as Paul Mahon, has been an active seller. Over the past three months, the same account reported seven Rule 144 sales totaling 66,000 shares for gross proceeds of about $19.38 million. Individual sale blocks were generally 11,000 shares, executed between 04/17/2025 and 06/26/2025 at prices that generated proceeds of $3.08鈥�$3.31 million per block.

While Rule 144 notices do not guarantee a sale will occur, they provide advance public disclosure of an insider or affiliate鈥檚 intent to transact. The filing also certifies that the seller is not in possession of undisclosed material adverse information and, if applicable, is operating under a Rule 10b5-1 plan.

Key take-aways for investors:

• Continuation of a steady liquidation pattern鈥攁n additional 11,000 shares planned after 66,000 shares already sold in the prior quarter.
• The cumulative 77,000 shares (0.17 % of shares outstanding) may point to portfolio diversification rather than a large strategic exit.
• No financial performance data or corporate developments are disclosed in the Form 144; the filing is limited to proposed share sales.

United Therapeutics (UTHR) filed a Form 4 disclosing that EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at $135.42 and immediately sold the same 11,000 shares on 26 Jun 2025 at weighted-average prices between $283.52 and $288.80, generating gross proceeds of roughly $3.1 million.

The sale, executed under a pre-arranged 10b5-1 plan adopted 24 Dec 2024, reduced Mahon鈥檚 direct holdings by about 23 % to 36,781 shares; he still holds 121,000 options. No other executives were involved.

This sizable insider disposition may influence investor sentiment even though it was pre-planned.

United Therapeutics (Nasdaq: UTHR) filed an 8-K covering its June 26 2025 annual meeting. Shareholders re-elected all 13 directors, approved the non-binding say-on-pay vote, and ratified Ernst & Young as auditor. The meeting also approved an amendment and restatement of the 2015 Stock Incentive Plan, adding 950,000 shares, extending the plan to April 24 2035, and increasing the Lead Independent Director retainer by $5,000. No other material financial or operational changes were disclosed.

United Therapeutics Corp. (UTHR) 鈥� Form 144 filing summary

Officer Paul A. Mahon has filed a Form 144 indicating his intent to sell 11,000 common shares of United Therapeutics on or after 26 Jun 2025 through Morgan Stanley Smith Barney. The shares have an estimated aggregate market value of $3.14 million. The company has 45.11 million shares outstanding, so the proposed sale represents roughly 0.024 % of shares outstanding.

Recent insider activity:

• During the past three months, Mahon has already sold 66,000 shares across seven transactions, generating $19.60 million in gross proceeds.
• If the newly-noticed 11,000-share tranche is executed, cumulative sales since 3 Apr 2025 will reach 77,000 shares (鈮� 0.17 % of outstanding).

The filing cites a 10b5-1 trading plan adopted on 24 Dec 2024, and the signer affirms no undisclosed material adverse information. No other financial data or corporate developments are disclosed in this notice.

Key takeaways for investors:

• Continued insider selling by a senior officer may be interpreted as a modestly negative sentiment signal, though the percentage of total shares is small.
• The existence of a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading.
• No operational, earnings, or strategic information is included; the filing is strictly a regulatory notice of planned sales.